Related Experiment Video
Updated: Jul 17, 2026
10:39
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
Testing the combination beta-blocker plus topiramate in refractory migraine
J Pascual1, M T Rivas, R Leira
1Service of Neurology, University Hospital, Salamanca, Spain. juliopascual@telefonica.net
Acta Neurologica Scandinavica
|January 11, 2007
Summary
Combining a beta-blocker and topiramate offers significant migraine relief for patients resistant to monotherapy. This combination therapy effectively reduced headache frequency in over 60% of refractory migraine sufferers.
Area of Science:
- Neurology
- Pharmacology
Background:
- Migraine is a debilitating neurological disorder.
- Patients refractory to monotherapy pose a treatment challenge.
- Beta-blockers and topiramate are established migraine treatments.
Purpose of the Study:
- To evaluate the efficacy and safety of combining a beta-blocker with topiramate.
- To assess this combination in patients previously unresponsive to monotherapy with these agents.
Main Methods:
- A cohort of 58 patients with refractory migraine received combined beta-blocker and topiramate treatment.
- Patients were assessed for response based on headache frequency reduction and adverse events.
Main Results:
- Over 60% of patients (36/48) achieved a >50% reduction in monthly headache frequency.
- The average monthly headache days decreased by 57% (from 15.1 to 6.5).
- 17% of patients discontinued treatment due to adverse events, which were generally mild-moderate.
Conclusions:
- Combination therapy with beta-blocker and topiramate is a viable strategy for refractory migraine.
- This approach offers complementary mechanisms of action for enhanced migraine control.
- Further investigation into this combination therapy is warranted for difficult-to-treat migraines.
